156 related articles for article (PubMed ID: 38482405)
1. Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer.
Ke Z; Xu Y; Shu Y; Wang C; Wu B; Zhang B; Xiang P; Hu X
Transl Cancer Res; 2024 Feb; 13(2):676-685. PubMed ID: 38482405
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Efficiency of Pan-Immune-Inflammation Value to Predict Prostate Cancer in Patients with Prostate-Specific Antigen between 4 and 20 ng/mL.
Zhu M; Zhou Y; Liu Z; Jiang Z; Qi W; Chen S; Wang W; Shi B; Zhu Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769469
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Role of inflammatory factors in prediction of Gleason score and its upgrading in localized prostate cancer patients after radical prostatectomy.
Wang S; Ji Y; Ma J; Du P; Cao Y; Yang X; Yu Z; Yang Y
Front Oncol; 2022; 12():1079622. PubMed ID: 36713540
[TBL] [Abstract][Full Text] [Related]
5. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
[TBL] [Abstract][Full Text] [Related]
7. Establishing a novel prediction model for improving the positive rate of prostate biopsy.
Tao T; Shen D; Yuan L; Zeng A; Xia K; Li B; Ge Q; Xiao J
Transl Androl Urol; 2020 Apr; 9(2):574-582. PubMed ID: 32420162
[TBL] [Abstract][Full Text] [Related]
8. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients.
March-Villalba JA; Martínez-Jabaloyas JM; Herrero MJ; Santamaría J; Aliño SF; Dasí F
Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S69-77. PubMed ID: 22559196
[TBL] [Abstract][Full Text] [Related]
9. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
[TBL] [Abstract][Full Text] [Related]
10. The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer.
Yu Z; Yuan M; Chen G
Eur J Med Res; 2023 Dec; 28(1):587. PubMed ID: 38093347
[TBL] [Abstract][Full Text] [Related]
11. Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment.
Mei JJ; Zhao YX; Jiang Y; Wang J; Yu JS
Cancer Manag Res; 2020; 12():4959-4968. PubMed ID: 32636672
[TBL] [Abstract][Full Text] [Related]
12. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer.
Yu M; Yang C; Wang S; Zeng Y; Chen Z; Feng N; Ning C; Wang L; Xue L; Zhang Z
Clin Chim Acta; 2020 Nov; 510():437-441. PubMed ID: 32791134
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Preoperative Prostate Health Index and Serum Testosterone Testing for Biochemical Recurrence after Radical Prostatectomy for Non-Metastatic Prostate Cancer.
Zhang C; Zhang Y; Niu N; Fu G
Arch Esp Urol; 2023 Dec; 76(10):787-795. PubMed ID: 38186072
[TBL] [Abstract][Full Text] [Related]
14. The Diagnostic Value of Serum TGF-β1, p2PSA Combined with PSA in Prostate Cancer.
Guo X; Sun X; Ye P
Altern Ther Health Med; 2023 Nov; ():. PubMed ID: 37971439
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
16. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
[TBL] [Abstract][Full Text] [Related]
17. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen nomogram to predict advanced prostate cancer using area under the receiver operating characteristic curve boosting.
Hashimoto T; Komori O; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Shishido T; Namiki K; Ohno Y
Urol Oncol; 2022 Apr; 40(4):162.e9-162.e16. PubMed ID: 35065881
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml
Gao XD; Miao Q; Zhang JL; Zhai JZ; Gui XM; Cai YH; Niu Q; Cai B
Asian J Androl; 2022; 24(2):195-200. PubMed ID: 34916475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
